Literature DB >> 22906942

Adaptation of a previously validated vaccination report card for use in adult vaccine clinical trials to align with the 2007 FDA Toxicity Grading Scale Guidance.

Josephine M Norquist1, Shazia S Khawaja, Cizely Kurian, T Christopher Mast, Kai-Li Liaw, Michael N Robertson, Barbara Evans, David Gutsch, Patricia Saddier.   

Abstract

The Adult/Adolescent Vaccination Report Card (VRC) was developed and validated by Merck in 1998 for use in vaccine clinical trials to collect information from trial subjects on complaints for both local and systemic events after vaccination. This short report describes the revision to the original validated VRC in order to align with the guidelines outlined in the 2007 FDA Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Since the VRC elicits trial subjects' self-reports of any adverse experiences (AE) occurring post vaccination, it was important that subsequent modifications of the VRC retained the original user-friendly characteristics while gathering the appropriate information to align with the FDA Guidance. A convenience sample of 15 participants (71% females, 87% white and mean (SD) age 45 (13) years was recruited to obtain feedback in order to revise the Adult/Adolescent VRC. Based on the feedback received, the following were slightly revised: ruler for the measurements of local systemic reactions, severity ratings, and general instructions. The revised VRC is currently being used in Merck vaccine clinical trials.

Entities:  

Mesh:

Year:  2012        PMID: 22906942      PMCID: PMC3579899          DOI: 10.4161/hv.21408

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  10 in total

1.  Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age.

Authors:  Stephen K Tyring; Francisco Diaz-Mitoma; Larry G Padget; Margarita Nunez; Gregory Poland; William M Cassidy; Nickoya D Bundick; Jianjun Li; Ivan S F Chan; Jon E Stek; Paula W Annunziato
Journal:  Vaccine       Date:  2006-10-30       Impact factor: 3.641

2.  Development and evaluation of a standardized questionnaire for identifying adverse events in vaccine clinical trials.

Authors:  P Coplan; L Chiacchierini; A Nikas; J Shea; A Baumritter; K Beutner; W Cassidy; M Sawyer; B Watson; J Heyse; H Guess
Journal:  Pharmacoepidemiol Drug Saf       Date:  2000-11       Impact factor: 2.890

3.  Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old.

Authors:  Myron J Levin; Anna-Barbara Moscicki; Lin-Ye Song; Terrence Fenton; William A Meyer; Jennifer S Read; Edward L Handelsman; Barbara Nowak; Carlos A Sattler; Alfred Saah; David R Radley; Mark T Esser; Adriana Weinberg
Journal:  J Acquir Immune Defic Syndr       Date:  2010-10       Impact factor: 3.731

4.  Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines.

Authors:  A Arguedas; C Soley; C Loaiza; G Rincon; S Guevara; A Perez; W Porras; O Alvarado; L Aguilar; A Abdelnour; U Grunwald; L Bedell; A Anemona; P M Dull
Journal:  Vaccine       Date:  2010-02-26       Impact factor: 3.641

5.  Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.

Authors:  Joost N Vermeulen; Joep M A Lange; Stephen K Tyring; Patrick H Peters; Margaret Nunez; Gregory Poland; Myron J Levin; Carrie Freeman; Ira Chalikonda; Jianjun Li; Jeffrey G Smith; Michael J Caulfield; Jon E Stek; Ivan S F Chan; Rupert Vessey; Florian P Schödel; Paula W Annunziato; Katia Schlienger; Jeffrey L Silber
Journal:  Vaccine       Date:  2011-12-07       Impact factor: 3.641

6.  An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.

Authors:  Timo Vesikari; Pierre Van Damme; Niklas Lindblad; Ulrich Pfletschinger; David Radley; Desmond Ryan; Scott Vuocolo; Richard M Haupt; Dalya Guris
Journal:  Pediatr Infect Dis J       Date:  2010-04       Impact factor: 2.129

7.  Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older.

Authors:  Santosh C Sutradhar; William W B Wang; Katia Schlienger; Jon E Stek; Jin Xu; Ivan S F Chan; Jeffrey L Silber
Journal:  Clin Vaccine Immunol       Date:  2009-03-04

8.  Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.

Authors:  Clayton D Harro; Michael N Robertson; Michelle A Lally; Lori D O'Neill; Srilatha Edupuganti; Paul A Goepfert; Mark J Mulligan; Frances H Priddy; Sheri A Dubey; Lisa S Kierstead; Xiao Sun; Danilo R Casimiro; Mark J DiNubile; John W Shiver; Randi Y Leavitt; Devan V Mehrotra
Journal:  AIDS Res Hum Retroviruses       Date:  2009-01       Impact factor: 2.205

9.  Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.

Authors:  Frances H Priddy; Deborah Brown; James Kublin; Kathleen Monahan; David P Wright; Jacob Lalezari; Steven Santiago; Michael Marmor; Michelle Lally; Richard M Novak; Stephen J Brown; Priya Kulkarni; Sheri A Dubey; Lisa S Kierstead; Danilo R Casimiro; Robin Mogg; Mark J DiNubile; John W Shiver; Randi Y Leavitt; Michael N Robertson; Devan V Mehrotra; Erin Quirk
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

10.  Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.

Authors:  Boris Kerzner; Alexander V Murray; Eric Cheng; Rudy Ifle; Peter R Harvey; Mark Tomlinson; Julie L Barben; Kimberly Rarrick; Jon E Stek; Mi-Ok Chung; Florian P Schödel; William W B Wang; Jin Xu; Ivan S F Chan; Jeffrey L Silber; Katia Schlienger
Journal:  J Am Geriatr Soc       Date:  2007-10       Impact factor: 5.562

  10 in total
  7 in total

1.  Evaluation of immunogenicity and safety of VARIVAX™ New Seed Process (NSP) in children.

Authors:  Shelly D Senders; Nickoya D Bundick; Jianing Li; Carol Zecca; Frans A Helmond
Journal:  Hum Vaccin Immunother       Date:  2017-12-11       Impact factor: 3.452

2.  A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL).

Authors:  Zoran Popmihajlov; Lei Pang; Elizabeth Brown; Amita Joshi; Shu-Chih Su; Susan S Kaplan; English D Willis
Journal:  Hum Vaccin Immunother       Date:  2018-09-05       Impact factor: 3.452

3.  Proposing a standardized assessment of COVID-19 vaccine-associated cutaneous reactions.

Authors:  Rhea Singh; Rowanne Ali; Sonya Prasad; Steven T Chen; Kimberly Blumenthal; Esther E Freeman
Journal:  J Am Acad Dermatol       Date:  2022-05-13       Impact factor: 15.487

4.  Skin Reaction Report Form: Development and Design of a Standardized Report Form for Skin Reactions Due to Medical Devices for Diabetes Management.

Authors:  Guido Freckmann; Sina Buck; Delia Waldenmaier; Eva Zschornack; Manuela Link; Nina Jendrike; Ines Obstfelder; Sara Vetrugno; Stefanie Kamann; Cornelia Haug
Journal:  J Diabetes Sci Technol       Date:  2020-03-22

5.  Pilot, double-blind, randomized, placebo-controlled clinical trial of the supplement food Nyaditum resae® in adults with or without latent TB infection: Safety and immunogenicity.

Authors:  Eva Montané; Ana Maria Barriocanal; Ana Lucía Arellano; Angelica Valderrama; Yolanda Sanz; Nuria Perez-Alvarez; Paula Cardona; Cristina Vilaplana; Pere-Joan Cardona
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

6.  Association between Recent Usage of Antibiotics and Immunogenicity within Six Months after COVID-19 Vaccination.

Authors:  Ka-Shing Cheung; Lok-Ka Lam; Ruiqi Zhang; Poh-Hwa Ooi; Jing-Tong Tan; Wai-Pan To; Chun-Him Hui; Kwok-Hung Chan; Wai-Kay Seto; Ivan F N Hung; Wai K Leung
Journal:  Vaccines (Basel)       Date:  2022-07-14

7.  Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients.

Authors:  Ka Shing Cheung; Lok Ka Lam; Rex Wan Hin Hui; Xianhua Mao; Ruiqi R Zhang; Kwok Hung Chan; Ivan Fn Hung; Wai Kay Seto; Man-Fung Yuen
Journal:  Clin Mol Hepatol       Date:  2022-05-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.